Shares of Cerenome (CNSY) cratered 9.4% to $3.35 after the freshly rebranded brain-cancer diagnostics and therapeutics company posted second-quarter results that badly missed expectations. The Houston-based firm, which combines precision diagnostics, targeted therapeutics, and artificial intelligence for central nervous system cancers, reported its Q2 financials on August 14. The numbers reveal a company spending aggressively while generating almost no revenue — and running low on cash to keep it going.

  • Revenue Collapsed Just as Analysts Expected Growth. Cerenome brought in just $411,000 in Q2 revenue, a jarring miss against the $1.11 million analyst consensus estimate for the quarter . For context, the prior quarter generated $1.03 million in revenue . A 60% sequential drop signals that the company's diagnostic test for detecting cancer spread to the brain — its only commercialized product — is struggling to gain traction with doctors and hospitals, despite a 2026 target of 150 million covered lives and 1,250 total tests performed .

  • Losses Are Growing Six Times Faster Than a Year Ago. Operating losses ballooned to $9.1 million from $1.5 million in Q2 2025 — a sixfold increase that reflects the cost of building out a commercial sales team, investing in AI platforms, and advancing clinical trials for its lead drug candidate across multiple brain cancer types . The $9.0 million net loss, or $1.31 per share, was far worse than the -$0.88 per-share loss analysts had forecast .

  • The Cash Runway Is Alarmingly Short. With just $8.6 million in cash and investments on hand — and burning roughly $9 million in a single quarter — Cerenome has less than one quarter's worth of operating funds at its current pace. The company has only 28 employees , yet its spending vastly outstrips its income. A capital raise — selling new shares, diluting existing holders — looks almost inevitable unless spending is cut drastically.

  • A New Name Doesn't Fix the Old Problems. Cerenome changed its name from Plus Therapeutics effective August 3, 2026 , and CEO Marc Hedrick touted "substantial progress" while promising acceleration "across all verticals." But full-year 2025 revenue was already declining at $5.21 million, down 10.5% year over year, while losses surged 72.5% to $22.39 million . Four analysts still rate the stock a "Strong Buy" with a $36 price target — roughly ten times today's price — but that target was set before this quarter's cash crisis became visible. Investors now face a stark question: Does the science justify the survival risk?